person · Reporting owner
Brakewood Harold Eugene
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immuneering CorpIMRX · Entity 5884 | Chief Business Officer | February 03, 2026 | February 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immuneering Corp
Report date February 03, 2026 · Filed February 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.91 · Expires 2036-02-03 | Direct | 140,000 |
Reported balance
After 2026-02-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-03 · Grant · Acquired 140,000 · Balance 140,000 F1: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2026 Filed Feb 5, 2026 13:37 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 140,000 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001790340-26-000032 · wk-form4_1770298673.xml · derivative · entry 1 Brakewood Harold Eugene · CIK 0001969578 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Class A Common Stock · 140,000 shares Expires 2036-02-03 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 14:09 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 5,250 | $4.76 | $24,990.00 |
DisclosureSEC source: 0001790340-26-000016 · wk-form4_1769004593.xml · nonDerivative · entry 1 Brakewood Harold Eugene · CIK 0001969578 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,050 Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 12:52 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 1,900 | $2.53 | $4,804.15 |
DisclosureSEC source: 0001790340-25-000085 · wk-form4_1750769533.xml · nonDerivative · entry 1 Brakewood Harold Eugene · CIK 0001969578 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,800 Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:17 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001790340-25-000028 · wk-form4_1738963057.xml · derivative · entry 1 Brakewood Harold Eugene · CIK 0001969578 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Class A Common Stock · 100,000 shares Expires 2035-02-05 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2025, and will be fully vested and exercisable on January 1, 2029. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:15 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 60,500 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001628280-24-024943 · wk-form4_1716495333.xml · derivative · entry 4 Brakewood Harold Eugene · CIK 0001969578 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,500 Underlying: Class A Common Stock · 60,500 shares Expires 2034-02-08 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:15 UTC | Immuneering Corp IMRX · Entity 5884 | Disposition to issuerStock Option · Derivative | 60,500 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001628280-24-024943 · wk-form4_1716495333.xml · derivative · entry 3 Brakewood Harold Eugene · CIK 0001969578 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 60,500 shares Expires 2034-02-08 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:15 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 165,000 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001628280-24-024943 · wk-form4_1716495333.xml · derivative · entry 2 Brakewood Harold Eugene · CIK 0001969578 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,000 Underlying: Class A Common Stock · 165,000 shares Expires 2033-03-31 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on January 23, 2024 and then in equal monthly installments over the subsequent three years, subject to Mr. Brakewood's continued employment through each applicable vesting date. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:15 UTC | Immuneering Corp IMRX · Entity 5884 | Disposition to issuerStock Option · Derivative | 165,000 | $0.00 Strike: $9.71 | $0.00 |
DisclosureSEC source: 0001628280-24-024943 · wk-form4_1716495333.xml · derivative · entry 1 Brakewood Harold Eugene · CIK 0001969578 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 165,000 shares Expires 2033-03-31 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on January 23, 2024 and then in equal monthly installments over the subsequent three years, subject to Mr. Brakewood's continued employment through each applicable vesting date. Read SEC document |
| March 22, 2024 Filed Mar 25, 2024 13:10 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 3,900 | $2.57 | $10,015.20 |
DisclosureSEC source: 0001790340-24-000040 · wk-form4_1711372194.xml · nonDerivative · entry 1 Brakewood Harold Eugene · CIK 0001969578 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,900 Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 21:21 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 60,500 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001790340-24-000012 · wk-form4_1707513692.xml · derivative · entry 1 Brakewood Harold Eugene · CIK 0001969578 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,500 Underlying: Class A Common Stock · 60,500 shares Expires 2034-02-08 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 20:54 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 165,000 | $0.00 Strike: $9.71 | $0.00 |
DisclosureSEC source: 0001969578-23-000003 · wf-form4_168055527152728.xml · derivative · entry 1 Brakewood Harold Eugene · CIK 0001969578 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,000 Underlying: Class A Common Stock · 165,000 shares Expires 2033-03-31 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on January 23, 2024 and then in equal monthly installments over the subsequent three years, subject to Mr. Brakewood's continued employment through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.